<VariationArchive RecordType="classified" VariationID="4684" VariationName="NG_008931.2:g.(188110_192927)_(194341_195522)del" VariationType="Deletion" Accession="VCV000004684" Version="2" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2023-04-02" DateCreated="2017-01-20" MostRecentSubmission="2017-01-20">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="19723" VariationID="4684">
      <GeneList>
        <Gene Symbol="VPS13A" FullName="vacuolar protein sorting 13 homolog A" GeneID="23230" HGNC_ID="HGNC:1908" Source="submitted" RelationshipType="asserted, but not computed">
          <Location>
            <CytogeneticLocation>9q21.2</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="9" Accession="NC_000009.12" start="77177534" stop="77421537" display_start="77177534" display_stop="77421537" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="9" Accession="NC_000009.11" start="79792360" stop="80032398" display_start="79792360" display_stop="80032398" Strand="+" />
          </Location>
          <OMIM>605978</OMIM>
        </Gene>
      </GeneList>
      <Name>NG_008931.2:g.(188110_192927)_(194341_195522)del</Name>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>9q21</CytogeneticLocation>
      </Location>
      <HGVSlist>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_033305.3" sequenceAccession="NM_033305" sequenceVersion="3" change="c.8212_8471del" MANESelect="true">
            <Expression>NM_033305.3:c.8212_8471del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_008931.2" sequenceAccession="NG_008931" sequenceVersion="2" change="g.(188110_192927)_(194341_195522)del">
            <Expression>NG_008931.2:g.(188110_192927)_(194341_195522)del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_033305.3" sequenceAccession="NM_033305" sequenceVersion="3" change="c.8211_8471del" MANESelect="true">
            <Expression>NM_033305.3:c.8211_8471del</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef Type="Allelic variant" ID="605978.0003" DB="OMIM" />
      </XRefList>
      <Comment DataSource="NCBI curation" Type="LocationOnGenomeAndProductNotAligned">The loss of exons 60 and 61 from the cDNA result from a genomic deletion of 5937 bp.  NCBI staff could not provide HGVS expressions for the genomic deletion because the paper by Ueno et al., 2001 (PubMed 11381254) did not publish the sequences of the primers used to size the deletion.</Comment>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NG_008931.2:g.(188110_192927)_(194341_195522)del AND Chorea-acanthocytosis" Accession="RCV000004948" Version="3">
        <ClassifiedConditionList TraitSetID="1286">
          <ClassifiedCondition DB="MedGen" ID="C0393576">Chorea-acanthocytosis</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>no assertion criteria provided</ReviewStatus>
            <Description DateLastEvaluated="2001-06-01" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2001-06-01" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2017-01-20" MostRecentSubmission="2017-01-20">
        <ReviewStatus>no assertion criteria provided</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">11381254</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="1286" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="805" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Acanthocytosis with neurologic disorder</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Levine-Critchley syndrome</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Chorea-acanthocytosis</ElementValue>
                <XRef ID="MONDO:0008695" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Choreaacanthocytosis</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Choreoacanthocytosis</ElementValue>
                <XRef ID="Choreoacanthocytosis/1384" DB="Genetic Alliance" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">CHAC</ElementValue>
                <XRef ID="GTR000501217" DB="Genetic Testing Registry (GTR)" />
                <XRef Type="MIM" ID="200150" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Chorea-acanthocytosis (ChAc) is characterized by a progressive movement disorder, cognitive and behavior changes, a myopathy that can be subclinical, and chronic hyperCKemia in serum. Although the disorder is named for acanthocytosis of the red blood cells, this feature is variable. The movement disorder is mostly limb chorea, but some individuals present with parkinsonism. Dystonia is common and affects the oral region and especially the tongue, causing dysarthria and serious dysphagia with resultant weight loss. Habitual tongue and lip biting are characteristic, as well as tongue protrusion dystonia. Progressive cognitive and behavioral changes resemble those in a frontal lobe syndrome. Seizures are observed in almost half of affected individuals and can be the initial manifestation. Myopathy results in progressive distal muscle wasting and weakness. Mean age of onset in ChAc is about 30 years, although ChAc can develop as early as the first decade or as late as the seventh decade. It runs a chronic progressive course and may lead to major disability within a few years. Life expectancy is reduced, with age of death ranging from 28 to 61 years.</Attribute>
                <XRef ID="NBK1387" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301561</ID>
                <ID Source="BookShelf">NBK1387</ID>
              </Citation>
              <XRef ID="2388" DB="Orphanet" />
              <XRef ID="C0393576" DB="MedGen" />
              <XRef ID="MONDO:0008695" DB="MONDO" />
              <XRef Type="MIM" ID="200150" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="25124" SubmissionDate="2019-12-18" DateLastUpdated="2017-01-20" DateCreated="2013-04-04">
        <ClinVarSubmissionID localKey="605978.0003_CHOREOACANTHOCYTOSIS" title="VPS13A, 260-BP DEL_CHOREOACANTHOCYTOSIS" />
        <ClinVarAccession Accession="SCV000025124" DateUpdated="2017-01-20" DateCreated="2013-04-04" Type="SCV" Version="3" SubmitterName="OMIM" OrgID="3" OrganizationCategory="resource" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2001-06-01">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species>human</Species>
              <AffectedStatus>not provided</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>literature only</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">In affected members of 3 Japanese families with choreoacanthocytosis (CHAC; 200150), Ueno et al. (2001) identified a homozygous 260-bp deletion in the VPS13A gene, leading to a truncated protein. The families originated from a small area in Japan, and haplotype analysis indicated a founder effect. Some of the patients' parents, who were heterozygous for the mutation, showed a slight degree of acanthocytosis in peripheral blood but no distinct neurologic abnormalities except for cryptogenic abducens palsy in 1 parent.</Attribute>
              <Citation>
                <ID Source="PubMed">11381254</ID>
              </Citation>
              <XRef DB="OMIM" ID="200150" Type="MIM" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="VPS13A" />
          </GeneList>
          <Name>VPS13A, 260-BP DEL</Name>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name Type="NonHGVS">260-BP DEL</Name>
          </OtherNameList>
          <XRefList>
            <XRef DB="OMIM" ID="605978.0003" Type="Allelic variant" />
          </XRefList>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">CHOREOACANTHOCYTOSIS</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="25124" TraitType="Disease" MappingType="Name" MappingValue="CHOREOACANTHOCYTOSIS" MappingRef="Preferred">
        <MedGen CUI="C0393576" Name="Chorea-acanthocytosis" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

